etravirine
Sign in to saveAlso known as TMC-125, ETR, Intelence
Etravirine (ETR,), sold under the brand name Intelence is an antiretroviral medication used for the treatment of HIV. Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson. In January 2008, the US Food and Drug Administration (FDA) approved its use for people with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United Stat
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 443748530
- Drug.image
- Etravirine structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150
- Drug.image2
- Etravirine ball-and-stick model.png
- Drug.width2
- 185
- Drug.tradename
- Intelence
- Drug.MedlinePlus
- a608016
- Drug.DailyMedID
- Etravirine
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AG04
- Drug.legal_AU
- S4
- Drug.legal_CA
- Schedule VI
- Drug.legal_UK
- POM
via Wikipedia infobox
Research
900 papers- Etravirine.2006
- Etravirine.Drugs · 2008
- Etravirine.Drugs of today (Barcelona, Spain : 1998) · 2008
- Etravirine.2012
- Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.Clinical pharmacokinetics · 2020
via PubMed
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Contraindication
- Adverse effects
- Mechanism of action
- Chemistry
- Research
- References
Etravirine (ETR,), sold under the brand name Intelence is an antiretroviral medication used for the treatment of HIV. Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI). Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine. Etravirine is marketed by Janssen, a subsidiary of Johnson & Johnson. In January 2008, the US Food and Drug Administration (FDA) approved its use for people with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008. It was also approved for use in Canada in April 2008.
Etravirine is licensed in the United States, Canada, Israel, Russia, Australia, New Zealand, and the European Union, and is under regulatory review in Switzerland.
Excerpted from Wikipedia’s “etravirine” article, available under the CC BY-SA 4.0 licence.